中药对复发性卵巢上皮癌腹水患者血CA125的影响

摘要

目的:探讨中药对复发性卵巢上皮癌腹水患者血糖抗原125(CA125)的影响.方法:选取2016年1月至2017年12月泰安市中心医院收治的复发性卵巢上皮癌合并腹水患者92例为研究对象.采用随机数字表法将患者随机分为观察组和对照组,每组46例. 2组均接受常规腹腔灌注化疗,观察组在此基础上加用中药治疗.治疗4周后进行疗效评价.治疗前后,分别采集空腹静脉血5 mL,检测血清CA125.统计2组治疗期间不良反应发生情况.结果:观察组和对照组总有效率分别为82.61%和60.87%,2组比较差异有统计学意义(P＜0.05).治疗前,2组血清CA125水平比较,差异无统计学意义(P＞0.05);治疗后,观察组血清CA125水平显著低于对照组(P＜0.05). 2组恶心呕吐、腹泻、白细胞减少、血小板减少和肾功能异常发生率比较,差异均无统计学意义(P＞0.05).结论:常规腹腔灌注化疗的同时联合应用中药抗化疗不良反应方可显著降低卵巢上皮癌腹水患者血清CA125水平,提高临床疗效,且安全可靠.%Objective:To investigate the effect of Chinese medicine on blood glucose antigen 125 (CA125) in patients with recur－rent epithelial ovarian cancer.Methods:A total of 92 patients with recurrent epithelial ovarian cancer and ascites who were admit －ted to our hospital from January 2016 to December 2017 were selected as study subjects.Patients were randomly divided into obser－vation group and control group using random number table method ,with 46 cases in each group.Both groups received conventional intraperitoneal chemotherapy ,and the observation group was treated with traditional Chinese medicine.After 4 weeks of treatment , the curative effect was evaluated.Before and after treatment ,5 mL of fasting venous blood was collected to detect serum CA 125.The incidence of adverse reactions during treatment in both groups was calculated.Results:The total effective rates of observation group and control group were 82.61% and 60.87% respectively,and there was significant difference between the two groups ( P ＜0.05).Before treatment,there was no significant difference in serum CA 125 levels between the two groups (P＞0.05).After treat－ment,the serum CA125 level was significantly lower in the observation group than in the control group ( P＜0.05).There was no significant difference in the incidence of nausea and vomiting ,diarrhea,leukopenia,thrombocytopenia and renal dysfunction between the two groups (P＞0.05).Conclusion:Conventional intraperitoneal infusion chemotherapy combined with the use of traditional Chinese medicine anti－chemotherapy side effects can significantly reduce serum CA 125 levels in patients with epithelial ovarian cancer ascites,improve clinical efficacy ,and is safe and reliable.